SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression =50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression

Brief description of study

Study JZQB is a global, multicenter, randomized, double-blind, placebo-controlled, Phase 3 study that will enroll participants with unresectable, advanced or metastatic KRAS G12C-mutant NSCLC into one of two parallel-running parts that will: . Compare LY3537982 in combination with pembrolizumab to placebo in combination with pembrolizumab as first-line treatment for participants with a tumor with PD-L1 expression =50% (Part A). . Compare LY3537982 in combination with pembrolizumab, pemetrexed and platinum to placebo in combination with pembrolizumab, pemetrexed and platinum as first-line treatment of participants with a tumor with PD-L1 expression 0 to 100% (Part B).


Clinical Study Identifier: s23-01224
ClinicalTrials.gov Identifier: NCT06119581
Principal Investigator: Joshua K Sabari.
Other Investigators: Samantha VanMaanen, Elka R Travis, Jessica Wang, Cristian C Papazoglu Statescu, Elaine Shum, Salman Rafi Punekar, James Newman, Danny Perlaza, Marissa Rybstein, David Mendoza, Melissa L Martinez, Sally Lau, Jeffrey G Schneider, Natalia Cherkassky, Kirby Rodriguez, Vamsidhar Velcheti.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.